The United Kingdom is currently facing a severe shortage of co-codamol, a painkiller taken by millions, which is expected to continue for at least four months. Pharmacists across the country are actively supporting distressed patients who rely on this medication, particularly the commonly prescribed 30mg/500mg dosage. Reports indicate that more than 1.25 million doses of co-codamol are dispensed each month, making the impact of this shortage particularly widespread and concerning.

Industry experts have projected that supplies of co-codamol will not stabilize until June 2026, raising alarms among NHS providers about the potential health implications of this extended shortage. NHS Grampian has publicly noted the shortage and has communicated to patients that supplies of co-codamol 30/500 tablets will be limited starting from early February 2026 through the summer months. This shortage not only affects this specific dosage but is expected to have repercussions on other strengths of co-codamol, complicating treatment options for many patients suffering from pain.

The ongoing unavailability of this essential painkiller has led to growing concerns among healthcare professionals about patient well-being and pain management strategies. With pharmacists stepping in to provide support, it highlights the necessity for the healthcare system to address supply chain issues and find alternatives for patients who depend on co-codamol for their relief. The situation emphasizes the critical importance of medication supply stability for public health.